Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER: [Lu-177]-PNT6555 in Select Solid Tumors
NCT05432193Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PNT6555 in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), esophageal cancer and 4 more, sponsored by Eli Lilly and Company. Primary endpoint: Treatment emergent adverse events at 24 weeks. Started Jul 2022; status: terminated.
02
Drugs
PNT6555
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)esophageal cancermelanomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05432193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432193.